Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms

Nobutaka Shimizu¹
Masahiro Nozawa¹
Koichi Sugimoto²
Yutaka Yamamoto¹
Takafumi Minami¹
Taiji Hayashi¹
Kazuhiro Yoshimura¹
Tokumi Ishii¹
Hirotugu Uemura¹

¹Department of Urology, Faculty of Medicine, Kinki University, Osaka, Japan
²Department of Urology, Sakai Hospital, Faculty of Medicine, Kinki University, Osaka, Japan

Objectives: This study was conducted to examine the therapeutic efficacy and anti-inflammatory effect of ramelteon in elderly patients with insomnia associated with lower urinary tract symptoms (LUTS), who visited our urology department.

Methods: The study included 115 patients (102 men, 13 women) who scored ≥4 on the Athens Insomnia Scale and who wished to receive treatment. The assessment scales for therapeutic efficacy included the International Prostate Symptom Score (IPSS) for LUTS and the Insomnia Severity Index (ISI) for sleep disorders. The high-sensitivity C-reactive protein (hs-CRP) test was used to objectively assess. The patients were treated with ramelteon (8 mg/day) for an average of 10 weeks and were then reexamined using the questionnaires and hs-CRP test to evaluate therapeutic efficacy.

Results: IPSS total scores declined significantly from 11.39 ± 8.78 to 9.4 ± 7.72. ISI total scores improved significantly from 11.6 ± 5.2 to 9.2 ± 5.3 (P < 0.0001). The levels of hs-CRP decreased significantly from 0.082 (standard deviation [SD] upper limit, 0.222; SD lower limit, −0.059) to 0.06 (SD upper limit, 0.152; SD lower limit, −0.032). The ISI scores ≥ 10 (n = 51) showed a weak correlation with the hs-CRP levels.

Conclusion: Ramelteon had a systemic anti-inflammatory effect and improved sleep disorders and LUTS, suggesting that it may be a useful treatment for patients with LUTS-associated insomnia.

Keywords: sleep disorders, inflammation, lower urinary tract symptoms, ramelteon

Introduction
In today’s society of high stress and nightshift work, there has been a surge in the number of people who suffer from insomnia or disturbed body rhythm, to the point where one out of five Japanese individuals complains of sleep disorder.¹ A study by the Institute of Public Health (now the National Institute of Public Health) showed that approximately one in 20 people had used sleeping pills in the previous month, with particularly high rates found among elderly individuals.² Sleep disorders can cause deterioration in the quality of life (QOL), induce inflammation, and put individuals at risk of developing lifestyle-related diseases and specifically, cardiovascular diseases.³,⁴

We previously reported that lower urinary tract symptoms (LUTS) and sleep disorders are closely related; the prevalence of the two increases as the population ages, and high LUTS scores are associated with a high prevalence of sleep disorders.⁵ Benzodiazepines (mainstream sleeping drugs) have a muscle relaxant effect that can result in staggering and falling. These adverse effects can last through the following morning, requiring that particular caution be exercised in elderly patients, who tend
to have a number of complications, such as nocturia. In fact, there have been reports of an increased death rate from staggering-associated falls, in people who rise to urinate during the night.\textsuperscript{6,7} Urination-related arousal has also been argued to compromise sleep quality in the elderly.\textsuperscript{8}

Ramelleon, a melatonin receptor (MT) agonist, is a drug with a novel mechanism of action. It induces sleep not through sedative action but rather, by adjusting the sleep–wake rhythm. The use of ramelteon has not induced staggering in elderly patients with insomnia.\textsuperscript{9} We previously used ramelteon to increase the nighttime bladder capacity of patients with nocturia-induced insomnia and found that it successfully reduced the number of nocturnal voids and improved sleep disorders.\textsuperscript{10} There has been only one study in which the use of ramelteon resulted in the improvement of both nocturia and overall LUTS.\textsuperscript{10} However, body rhythm disturbances caused by irregular shifts at work have been reported to result in inflammation induced by transient sleep disorders.\textsuperscript{11} Thus, in the present study, we administered ramelteon to patients with LUTS-associated insomnia to examine the drug’s ability to improve sleep disorders and LUTS, and we used an inflammatory marker – high sensitivity C-reactive protein (hs-CRP) – to evaluate the objective findings.

**Subjects and methods**

This was an open and nonrandomized study. The Insomnia Severity Index (ISI)\textsuperscript{12} and International Prostate Symptom Score (IPSS)\textsuperscript{13} questionnaires were approved by the ethics committee of Kinki University. Consent was obtained from patients before the start of the study. Study subjects were selected from among those who received outpatient treatment at the Department of Urology, Kinki University Faculty of Medicine, between November 2011 and May 2012 and who complained of insomnia, with an Athens Insomnia Scale (AIS)\textsuperscript{14} score $\geq 4$, for which they wished to receive treatment while continuing on their current therapy. The study included 115 patients (102 men, mean age 72.5 $\pm$ 10.0 years; and 13 women, mean age 70.5 $\pm$ 8.0 years), from whom the interview sheet could be collected before and after ramelteon treatment (Table 1).

The subjects took one 8 mg ramelteon tablet once a day for 10 weeks. Because ramelteon, as a melatonin receptor agonist, has a mechanism of action that is completely different from that of existing benzodiazepines and nonbenzodiazepines, the study allowed its concomitant use with other hypnotic agents, and no changes were made to the subjects’ existing treatment regimens during the evaluation period. In addition, when combined, the dose of the $\alpha_1$-blocker and the anticholinergic drugs targeting LUTS remained unaltered during the evaluation period. Patients who had a history of hypersensitivity to ramelteon, severe hepatic dysfunction, or who were currently taking fluvoxamine, were excluded from the study.

### Sleep disorders

Subjects were first evaluated for the use of a hypnotic agent and were then evaluated with the AIS, a scale developed in the Worldwide Project on Sleep and Health that was launched by the World Health Organization. The scale scores were interpreted as: $\leq 4$, no concern about sleep disorder; 4–5, sleep disorder slightly suspected; and $\geq 6$, sleep disorder suspected. Subjects were assessed using the *International Classification of Sleep Disorders, second edition (ICSD-2)*\textsuperscript{15} to determine whether they had any of the following: subjective insomnia; presence of insomnia within an environment suited for sleep; and functional impairments during the day (eg, daytime sleepiness, impaired attentive ability, and impaired concentration). An evaluation of insomnia improvement was then performed using a questionnaire survey that was based on a combination of the ISI and a subjective symptom improvement scale investigating: ease of falling asleep, arousal during nighttime sleep, the presence of a refreshed feeling in the morning, daytime drowsiness, and staggering. Sleeping disorders were classified into four types: (1) insomnia; (2) hypersomnia; (3) sleep apnea; and (4) circadian rhythm disorder. This study focused only on the evaluation of insomnia.

### LUTS

The IPSS is an eight-question (seven symptom questions plus one QOL question) written screening tool that was designed to screen for, rapidly diagnose, track the symptoms of, and

---

**Table 1** Characteristics of patients with insomnia and lower urinary tract symptoms

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean $\pm$ SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>$n$</td>
<td>115</td>
</tr>
<tr>
<td>Gender: male/female</td>
<td>102/13</td>
</tr>
<tr>
<td>Age (years)</td>
<td>72.3 $\pm$ 9.8</td>
</tr>
<tr>
<td>IPSS total</td>
<td>11.39 $\pm$ 8.78</td>
</tr>
<tr>
<td>AIS</td>
<td>6.4 $\pm$ 3.6</td>
</tr>
<tr>
<td>ISI</td>
<td>11.6 $\pm$ 5.2</td>
</tr>
<tr>
<td>Study period (weeks)</td>
<td>10.3 $\pm$ 5.1</td>
</tr>
</tbody>
</table>

**Notes:** Values are expressed as means $\pm$ SD.

**Abbreviations:** AIS, Athens Insomnia Scale; ISI, Insomnia Severity Index; BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; SD, standard deviation.
propose the management of benign prostatic hyperplasia (BPH). It is currently used to evaluate BPH and a wide range of other LUTS in both men and women. The seven symptom questions probe: feeling of incomplete emptying; daytime frequency; intermittency; urgency; slow stream; hesitancy; and nocturia. These questions refer to the period during the previous month and are rated on a scale of 1–5 for a maximum of 35 points. The QOL question is assigned a score of 1–6. Total scores of 0–7 represent mild symptoms, 8–9 represent moderate symptoms, and ≥20 represent severe symptoms.

**QOL**
The QOL subscale (0, delighted; 1, pleased; 2, mostly satisfied; 3, mixed; 4, mostly dissatisfied; 5, unhappy; and 6, terrible) of the IPSS questionnaire was also used.

**Evaluation of inflammation**
For patients whose hs-CRP levels could be measured biochemically before and after ramelteon treatment, the association between inflammation and improvements in sleep disorders and LUTS was examined. When we were able to collect blood at other opportunities, we used this CRP data instead. While a urinary tract infection was not present in any of these cases, information about potential confounding variables (eg, smoking, hypertension, and diabetes) was collected. A 7700 Hitachi Automatic Analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan) was used to measure hs-CRP.

**Statistical analysis**
The PASW Statistics 18.02 software package for Windows (IBM, Armonk, NY, USA) was used for the statistical analyses. Changes in IPSS scores, QOL subscores, and ISI scores were evaluated using the Wilcoxon test, whereas the correlation between the ISI and IPSS scores was evaluated using the Spearman rank correlation coefficient. Geometric means and standard deviations (SD) were calculated for hs-CRP levels as a measure of the anti-inflammatory effect. A paired t-test was performed to evaluate the relationship between changes in ISI scores and changes in hs-CRP levels. The relationship between the changes in IPSS scores and the changes in hs-CRP levels was evaluated using the Spearman rank correlation coefficient.

**Results**
The primary underlying disease was prostatic hyperplasia in 47 subjects, prostate cancer in 34 subjects, overactive bladder in 47 subjects, and neurogenic bladder in two subjects, while 16 subjects had nocturia only (Table 1). The total number of these subjects exceeded 115 because some subjects had comorbidities. Fifty-two patients had difficulty falling asleep, 72 were aroused during sleep, 72 had problem waking up too early, and seven were dissatisfied with sleep.

**Changes in IPSS scores and QOL subscores**
The IPSS total scores declined from 11.39 ± 8.78 to 9.4 ± 7.72 (P = 0.0013). Significant improvements were observed in the scores for storage symptoms (frequency + urgency + nocturia), which declined from 5.83 ± 3.87 to 4.72 ± 3.57 (P = 0.0003); voiding symptoms (intermittency + slow stream + hesitancy), which changed from 4.18 ± 4.35 to 3.62 ± 3.97 (P = 0.0487); nocturia, which changed from 2.43 ± 1.29 to 2.04 ± 1.31 (P = 0.0004); and QOL, which changed from 3.59 ± 1.52 to 3.07 ± 1.51 (P = 0.0009) (Figure 1).

**Changes in ISI scores**
Significant improvements were observed in the scores for: (1) difficulty falling asleep, which changed from 1.3 ± 1.0 to 0.9 ± 0.9 (P = 0.0002); (2) arousal during sleep, which changed from 1.7 ± 1.0 to 1.4 ± 1.0 (P = 0.0021); (3) waking up too early, which changed from 1.8 ± 1.2 to 1.3 ± 1.1 (P < 0.0001); (4) level of dissatisfaction with sleep, which changed from 2.5 ± 2.1 (P < 0.0001); (5) interference with daily functioning, which changed from 1.3 to 1.1 (P = 0.0128); (6) noticeability to others, which changed from 1.3 to 1.1 (P = 0.0289); (5) the level of worry/distress, which changed from 1.5 ± 0.28 to 1.2 ± 1.0 (P = 0.0003); and for (7) the total score, which changed from 11.6 ± 5.2 to 9.2 ± 5.3 (P < 0.0001) (Figures 2 and 3).

**Correlation between ISI and IPSS scores**
A weak correlation (r = 0.278) was observed between the changes in the ISI and IPSS scores (P = 0.0026) (Figure 4). The score of patients arousing during sleep correlated with the amount of residual urine (r = 0.414, P < 0.0001), disrupted urine flow (r = 0.434, P < 0.0001), and voiding (r = 0.460, P < 0.0001) subscores. The scores of patients dissatisfied with sleep showed correlation with the amount of residual urine (r = 0.434, P < 0.0001), the daytime urinary frequency (r = 0.459, P < 0.0001), disrupted urine flow (r = 0.428, P < 0.0001), voiding (r = 0.429, P < 0.0001), and storage (r = 0.447, P < 0.0001) subscores. The nocturia score also correlated with the subscore of patients dissatisfied with their sleep (r = 0.295, P < 0.0014).

**Anti-inflammatory effect**
The changes in hs-CRP levels are shown in Figure 5. The geometric mean before treatment was 0.082 (SD upper
Storage subscore
Score 0–21

Voiding subscore
Score 0–21

Frequency of nocturia
Score 0–4

QOL
Score 0–6

M ± SD (n = 115) Wilcoxon test

Figure 1 Change in storage subscores, voiding subscores, nocturia frequency, and quality of life before and after ramelteon administration. Notes: Values were expressed as mean ± SD (n = 115), Wilcoxon test. IPSS storage subscores were based on daytime frequency + urgency + nocturia; IPSS voiding subscores were based on intermittency + slow stream + hesitancy. Abbreviations: IPSS, International Prostate Symptom Score; QOL, quality of life; SD, standard deviation.

Discussion
In the present study, ISI total scores significantly declined from 11.6 ± 5.2 to 9.2 ± 5.3, below the pathological threshold cut-off point of 10. This finding demonstrated the effect of ramelteon in improving sleep disorders, with significant improvements observed in storage symptoms, voiding symptoms, nocturia, and QOL. This study also found that ramelteon treatment improved sleep quality, which in turn improved LUTS. Although the mechanism for the improvement of these symptoms is not yet clear, it is presumably related to LUTS and sleep disorders, as shown by an earlier report that the bladder has a “body clock” that is responsible for the circadian rhythm in urine collection, while clock genes are involved in the circadian rhythm in voiding.16

Ramelteon treatment significantly reduced hs-CRP levels by 26.8%. Inflammation and oxidation are closely related, and the antioxidant effect of melatonin is thought to be a direct result of its potent radical-scavenging ability, although recent reports have also suggested that the effect occurs via the MT receptor.17,18 It has also been reported that ramelteon, which shows high affinity only for the MT1 and MT2 receptors, improved hepatic function and liver perfusion in models of hepatic dysfunction caused by hemorrhagic shock, even though it was not shown to have direct antioxidant effect.19

The same report also confirmed that at least part of the effect was mediated by MT receptors and that ramelteon reduced nicotinamide adenine dinucleotide phosphate (NADPH), which is involved in oxidative stress. Based on these reports,
we believe that the declines seen in hs-CRP levels in the present study may have involved an antioxidant effect caused by MT receptor stimulation.

It has been reported that transient sleep disorders caused by body rhythm disturbances owing to irregular shifts at work induce inflammation. The significant correlation
between ISI scores and hs-CRP levels obtained in subjects who scored $\geq 10$ on the ISI scale, namely, those who were above the pathological threshold, suggests that the ramelteon treatment–induced sleep-quality improvements may have indirectly induced the anti-inflammatory effect. A report from a study conducted in 1452 Chinese men showed an association between hs-CRP levels and LUTS, in which the higher the former, the more severe was the latter. The present study did not find a definitive correlation between changes in hs-CRP levels and changes in IPSS scores; this may have been because hs-CRP levels are not determined solely by LUTS but are affected by systemic conditions, or may have been the result of differences in patient demographics or the small number of subjects. The study was not placebo controlled and a placebo effect cannot be completely excluded. Since the LUTS examination was only a subjective evaluation, an objective examination of the effect of uroflometry is required.

**Conclusion**

Ramelteon had a systemic anti-inflammatory effect and improved both sleep disorders and LUTS. These results suggest that ramelteon may be a useful treatment option for patients with LUTS-associated insomnia.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


